Biomerica Inc (BMRA) Stock Price & Analysis
Biomerica Inc (BMRA) fell 0.92% to USD 2.05 as of June 10, 2026 at 06:50 UTC, according to Nexqual real-time market data.
BMRA last closed at USD 2.07; the session ranged USD 2.03–2.19 on volume of 42,924 shares. Market capitalization is $6.34M, with a 52-week range of USD 1.87–4.6 (NCM). Source: Nexqual, June 10, 2026 at 06:50 UTC.
Key Statistics (as of June 10, 2026 at 06:50 UTC)
| Price | USD 2.05 |
|---|---|
| Change | ▼ 0.92% (down) |
| Previous Close | USD 2.07 |
| Open | USD 2.03 |
| Day Range | USD 2.03 – 2.19 |
| 52-Week Range | USD 1.87 – 4.6 |
| Volume | 42,924 shares |
| Market Cap | $6.34M |
| Exchange | NCM |
Technical Analysis (BMRA)
Nexqual's technical model rates BMRA "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 06:50 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.96 (neutral) |
| vs SMA50 | Below (USD 2.22) |
| MACD | -0.02 (negative) |
Analyst Ratings (BMRA)
Wall Street analysts rate BMRA "None", per Nexqual as of June 10, 2026 at 06:50 UTC.
| Consensus Rating | None |
|---|
Earnings (BMRA)
Source: Nexqual, June 10, 2026 at 06:50 UTC.
Financials & Fundamentals (BMRA)
| Total Revenue | $4.33M |
|---|---|
| Revenue Growth (YoY) | -11.80% |
| Gross Margin | +4.37% |
| Operating Margin | -131.51% |
| Profit Margin | -96.46% |
| ROE | -94.32% |
| Debt / Equity | 5.82 |
| Current Ratio | 2.64 |
| Total Cash | $1.34M |
| Total Debt | $193,000 |
| Free Cash Flow | $-2.03M |
Source: Nexqual, June 10, 2026 at 06:50 UTC.
Financial Health Score (BMRA)
Nexqual rates Biomerica Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 06:50 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $1M cash, no debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Critical — ROE -94%, ROA -54.6% |
Ownership (BMRA)
| Insider Ownership | +15.24% |
|---|---|
| Institutional Ownership | +3.62% |
| Shares Outstanding | 3.09M |
| Float | 2.77M |
| Short % of Float | +2.92% |
Source: Nexqual, June 10, 2026 at 06:50 UTC.
Leadership (BMRA)
Biomerica Inc is led by Zackary S. Irani (age 59), CEO & Director, per Nexqual as of June 10, 2026 at 06:50 UTC.
| CEO & Director | Zackary S. Irani (age 59) |
|---|---|
| Executive Vice-Chairman of the Board & Corporate Secretary | Allen C. Barbieri (age 67) |
| Director of Manufacturing & Technical Operations | Lucy Liu |
Major Backers & Investors (BMRA)
Notable institutional backers of Biomerica Inc include Fidelity, LPL Financial LLC, NewEdge Advisors, LLC, according to Nexqual as of June 10, 2026 at 06:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.61% |
| LPL Financial LLC | 0.35% |
| NewEdge Advisors, LLC | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.81% |
| Vanguard Group | 1.15% |
| BlackRock | 0.6% |
Source: Nexqual, June 10, 2026 at 06:50 UTC.
From Biomerica Inc's Latest SEC 10-K Filing (filed 2025-08-29)
Key Strengths & Strategy (as disclosed to the SEC)
- While we strive to maintain the quality of our product brands through these license agreements, we cannot guarantee that licensees will always act in a manner that preserves the value of our proprietary rights or reputation.   LICENSE OF THIRD-PARTY INTELLECTUAL PROPERTY   On occasion, we in-licensed both exclusive and non-exclusive rights to intellectual property and patents owned by third parties.
- We have filed patents globally to protect the use of inFoods® diagnostic technology for these indications, with patents issued in the United States and multiple foreign jurisdictions, and others in review or prosecution.   Our research and development efforts have also led to the FDA 510(k) clearance of hp+detect™, a proprietary diagnostic test for detecting Helicobacter pylori (H. pylori) and monitoring treatment.
- To safeguard our proprietary rights in products and services, we utilize copyright, trademark, patent, service mark, and trade secret laws, alongside contractual restrictions.
- However, these measures may not entirely prevent unauthorized use or disclosure of our technology.     In the past, we have licensed and may continue to license certain proprietary rights, such as trademarks, patents, trade secrets, or copyrighted material, to third parties.
Partnerships
- By removing the foods identified as problematic, patients can achieve relief from IBS symptoms.   We have introduced our inFoods® product to gastroenterology ("GI") physician groups in multiple states and regions, including collaboration with one of the largest GI groups in the U.S.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AYTU | Aytu BioPharma, Inc. | USD 2.3 | ▲ 2.22% |
| BNBX | BNB Plus Corp. | USD 0.53 | ▼ 2.78% |
| CFOR | OpGen, Inc. | USD 2 | ▲ 300% |
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.11 | ▼ 2.63% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:50 UTC. This page is informational and not investment advice.